Research
Hormonal
Semaglutide reduces the incidence of major cardiovascular adverse events (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) in patients with pre-existing cardiovascular disease and overweight/obesity, regardless of diabetes status.
If you have existing heart disease and are overweight, semaglutide may significantly lower your risk of heart attack, stroke, or cardiovascular death. This benefit exists even if you do not have diabetes.
StrongSupportsVERY_HIGH confidence
Recently, it has been reported that in patients with pre-existing cardiovascular disease (CVD) and overweight/obesity but without diabetes, semaglutide significantly reduces the incidence of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke compared to placebos (the SELECT trial).
Why this rating
Based on the SELECT trial, a major cardiovascular outcome trial.
Source
Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population
Francesco Natale et al. · Journal of Cardiovascular Development and Disease · 2024
narrative_reviewCited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →